Milestone Pharmaceuticals presented new data from a post-hoc analysis of the Phase 3 NODE-301 trial evaluating etripamil nasal spray, a short-acting calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT). The analysis demonstrated that etripamil significantly decreased heart rate (HR) prior to conversion to sinus rhythm (SR). The HR changes occurred within 5 minutes and were sustained for 60 minutes. The data were featured in a poster presentation at the American Heart Association (AHA) Scientific Sessions 2021 held November 13-15, 2021. A copy of the presentation can be found here.
NODE-301 enrolled a total of 431 patients across 65 sites in the U.S. and Canada. The event-driven, Phase 3 efficacy trial assessed etripamil versus placebo for terminating supraventricular tachycardia (SVT) episodes in a medically unsupervised setting. This analysis assessed the effect of etripamil on HR during the SVT episode and prior to conversion to SR, as well as the correlation of HR with patient-reported outcomes in 150 patients (etripamil, n=102; placebo, n= 48).
Patients treated with etripamil experienced a significantly greater reduction in mean HR fr...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).